Cellectis S.A.
CLLS- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001627281
No open-market purchases or sales by Cellectis S.A. insiders were filed in the last 90 days; 27 institutions reported holding it in 13F filings for Q2 2026, worth $28.4M in total; no superinvestor holds it.
Q3 2025 vs. Q2 2025
How the institutions holding Cellectis S.A. changed between Q2 2025 and Q3 2025.
All holders in Q3 2025All holders in Q2 2025
| Measure | Q2 2025 | Q3 2025 | Change |
|---|---|---|---|
| Holders | 24 | 28 | +4 |
| Shares | 11.8M | 8.31M | −3.45M (−29.3%) |
| Value | $17.9M | $23.7M | +$5.83M (+32.7%) |
New holders (7)
Institutions that held Cellectis S.A. at the end of Q3 2025 but not at the end of Q2 2025.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Citadel Advisors LLC | 221,959 | $632.6K | 0.00% |
| Virtu Financial LLC | 25,211 | $72.0K | 0.00% |
| Delaney Dennis R | 24,000 | $68.4K | 0.03% |
| Baird Financial Group, Inc. | 11,090 | $31.6K | 0.00% |
| Marshall Wace, LLP | 10,435 | $29.7K | 0.00% |
| Atlantic Union Bankshares Corp | 1,500 | $4.28K | 0.00% |
| Citigroup Inc | 990 | $2.82K | 0.00% |
Sold out (3)
Institutions that held Cellectis S.A. at the end of Q2 2025 and filed for Q3 2025 without it.
| Institution | Shares, Q2 2025 | Value, Q2 2025 |
|---|---|---|
| UBS Asset Management Americas Inc | 3,178,620 | $4.85M |
| Acadian Asset Management LLC | 11,747 | $17.0K |
| Raymond James Financial Inc | 1,132 | $1.73K |